DNTH vs. BCYC, NRIX, EOLS, SLN, YMAB, PRTC, COGT, IRON, PHAR, and SVRA
Should you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Bicycle Therapeutics (BCYC), Nurix Therapeutics (NRIX), Evolus (EOLS), Silence Therapeutics (SLN), Y-mAbs Therapeutics (YMAB), PureTech Health (PRTC), Cogent Biosciences (COGT), Disc Medicine (IRON), Pharming Group (PHAR), and Savara (SVRA). These companies are all part of the "pharmaceutical preparations" industry.
Dianthus Therapeutics (NASDAQ:DNTH) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, community ranking, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.
Dianthus Therapeutics currently has a consensus price target of $42.40, indicating a potential upside of 97.21%. Bicycle Therapeutics has a consensus price target of $46.86, indicating a potential upside of 106.15%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Dianthus Therapeutics.
47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 16.6% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 10.2% of Bicycle Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Bicycle Therapeutics received 110 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Dianthus Therapeutics an outperform vote while only 68.39% of users gave Bicycle Therapeutics an outperform vote.
In the previous week, Bicycle Therapeutics had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 5 mentions for Bicycle Therapeutics and 2 mentions for Dianthus Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.54 beat Dianthus Therapeutics' score of -0.20 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.
Dianthus Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -669.72%. Dianthus Therapeutics' return on equity of -45.49% beat Bicycle Therapeutics' return on equity.
Dianthus Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.
Dianthus Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics.
Summary
Dianthus Therapeutics and Bicycle Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Dianthus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dianthus Therapeutics Competitors List
Related Companies and Tools
